Standard BioTools Inc’s recent filing unveils that its Director Casdin Partners Master Fund, L acquired Company’s shares for reported $0.45 million on Nov 12 ’25. In the deal valued at $1.19 per share,375,000 shares were bought. As a result of this transaction, Casdin Partners Master Fund, L now holds 62,050,000 shares worth roughly $76.94 million.
Then, Casdin Partners Master Fund, L bought 300,000 shares, generating $358,800 in total proceeds. Upon buying the shares at $1.20, the Director now owns 61,675,000 shares.
Before that, Casdin Partners Master Fund, L bought 275,000 shares. Standard BioTools Inc shares valued at $321,915 were divested by the Director at a price of $1.17 per share. As a result of the transaction, Casdin Partners Master Fund, L now holds 61,375,000 shares, worth roughly $76.11 million.
TD Cowen downgraded its Standard BioTools Inc [LAB] rating to a Hold from a a Buy in a research note published recently. A number of analysts have revised their coverage, including KeyBanc Capital Markets’s analysts, who decreased its forecast for the stock in late February from “an Overweight” to “a Sector weight”. TD Cowen began covering LAB with “Buy” recommendation on April 16, 2024. Jefferies started covering the stock on April 04, 2024. It rated LAB as “a Buy”.
Price Performance Review of LAB
On Friday, Standard BioTools Inc [NASDAQ:LAB] saw its stock jump 3.33% to $1.24. Over the last five days, the stock has gained 9.73%. Standard BioTools Inc shares have fallen nearly -39.51% since the year began. Nevertheless, the stocks have fallen -29.14% over the past one year. While a 52-week high of $2.25 was reached on 01/15/25, a 52-week low of $0.92 was recorded on 05/23/25.
Levels Of Support And Resistance For LAB Stock
The 24-hour chart illustrates a support level at 1.1800, which if violated will result in even more drops to 1.1200. On the upside, there is a resistance level at 1.2800. A further resistance level may holdings at 1.3200.
How much short interest is there in Standard BioTools Inc?
A steep rise in short interest was recorded in Standard BioTools Inc stocks on 2025-10-31, dropping by -0.6 million shares to a total of 11.45 million shares. Yahoo Finance data shows the prior-month short interest on 2025-09-30 was 12.05 million shares. There was a decline of -5.21%, which implies that there is a negative sentiment for the stock.
The most recent change occurred on July 12, 2023 when KeyBanc Capital Markets began covering the stock and recommended ‘”an Overweight”‘ rating along with a $4 price target.
